

NOTICE: This is a translation of a notice in Japanese issued on June 25, 2014 and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

Securities code: 4536

June 25, 2014

**RESOLUTION NOTICE OF
THE 102ND ANNUAL GENERAL MEETING OF SHAREHOLDERS OF
SANTEN PHARMACEUTICAL CO., LTD.**

Dear Shareholder:

We hereby inform you of the reports and the resolutions that were made, as set forth below, in the 102nd Annual General Meeting of Shareholders of the Company that was held today.

Reports:

1. Reports on the Business Report, Consolidated Financial Statements and Financial Statements for the 102nd Business Term (April 1, 2013 to March 31, 2014)
2. Reports on the Audit Reports by the Accounting Auditors and the Board of Corporate Auditors on the Consolidated Financial Statements for the 102nd Business Term (April 1, 2013 to March 31, 2014)

As regards the items set forth above, the contents thereof were reported.

Resolved Items:

Proposal No. 1: Appropriation of Surplus

This item was approved as per the original proposal. The term-end dividends of profits were resolved to be JPY 50 per share. Consequently, the total dividends for the annual business term, including the interim dividends previously distributed are JPY 100 per share.

Proposal No. 2: Appointment of Five (5) Directors

As regards this item, Akira Kurokawa, Sadatoshi Furukado, Noboru Kotani, Akihiro Okumura and Takayuki Katayama were appointed as per the original proposal; each of them assumed their respective offices.

Noboru Kotani, Akihiro Okumura and Takayuki Katayama are Outside Directors.

Proposal No. 3: Appointment of Two (2) Corporate Auditors

As regards this item, Yoshihiro Noutsuka and Koichi Matsuzawa were appointed as per the original proposal; each of them assumed their respective offices.

Koichi Matsuzawa is an Outside Corporate Auditor.

Yours very truly,

Akira Kurokawa
President & CEO

SANTEN PHARMACEUTICAL CO., LTD.

9-19, Shimoshinjo 3-chome, Higashiyodogawa-ku, Osaka, Japan

ANNOUNCEMENT

At the Board of Directors meeting, which was held after the close of this Annual General Meeting of Shareholders, Akira Kurokawa was appointed as President and CEO. He assumed the said offices.

As a result thereof, the Directors and Corporate Auditors of the Company and Corporate Officers of the Company on and after July 1, 2014 shall be as follows:

Directors and Corporate Auditors

Akira Kurokawa	President and CEO
Sadatoshi Furukado	Director Vice President, Executive Corporate Officer Japan Business and Human Resources Development
Noboru Kotani *	Director
Akihiro Okumura *	Director
Takayuki Katayama *	Director
Yoshihiro Noutsuka	Standing Corporate Auditor
Yasuaki Tsuchiya**	Corporate Auditor
Yutaka Mizuno **	Corporate Auditor
Koichi Matsuzawa **	Corporate Auditor

* Outside Directors are Independent Officers (as set forth under Article 436-2, Paragraph 1 of the Securities Listing Regulations of the Tokyo Stock Exchange, Inc.; hereinafter, the same classification shall apply.)

**Outside Corporate Auditors are Independent Officers.

Corporate Officers (excluding Corporate Officers who are also Members of the Board)

Masamichi Sato	Senior Corporate Officer Head of Santen European Group President of Santen Holdings EU B.V.
Takeshi Ito	Senior Corporate Officer Head of Japan Sales and Marketing, Prescription Pharmaceuticals
Naveed Shams	Senior Corporate Officer Chief Scientific Officer (CSO) Head of Global Research and Development President & CEO of Santen Inc.
Jyrki Liljeroos	Corporate Officer President of Santen Oy
Kenji Morishima	Corporate Officer Head of Global Pharmaceutical Technology Development
Akihiro Tsujimura	Corporate Officer Head of Asia Division
Atutoshi Ota	Corporate Officer Head of Human Resources Development and CSR Division
Akio Kimura	Corporate Officer Head of Global Quality Compliance
Kazuo Koshiji	Corporate Officer Chief Financial Officer (CFO) Head of Finance and Administration Division
Takashi Kaneko	Corporate Officer Head of Global Clinical Development and Medical Affairs Representative, Japan Research and Development
Noriaki Yamamoto	Corporate Officer Chief Information Officer (CIO) Head of Information Systems Division
Hiroyuki Yamazaki	Corporate Officer Head of Japan Prescription Pharmaceuticals Sales
Keizo Nakada	Corporate Officer Head of Global Product Supply

End.